Sandoz Does Not Infringe Canadian Rapaflo Patent
But Generics Firm Fails To Convince Federal Court On Invalidity
Sandoz has succeeded in convincing a Canadian court that its generic version of Rapaflo does not infringe a formulation patent for silodosin capsules, although the firm’s invalidity claims fell on deaf ears.
